Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in Refractory Eyelid Dermatitis
NCT06684522Phase 1Recruiting
- Sponsor
- Northwestern University
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of upadacitinib in eyelid dermatitis, sponsored by Northwestern University. Primary endpoint: Investigator Global Assessment at 12 weeks. Started Dec 2025; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
eyelid dermatitis
Beyond the preview
Go deeper on NCT06684522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06684522.